Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei citing the prospects of its LY3298176, a GIP and GLP-1 dual receptor agonist presented at EASD 54th Annual Meeting, which he believes "meaningfully improves" the company's long-term growth prospects. 2. Helmerich & Payne (HP) upgraded to Overweight from Equalweight at Capital One. 3. Canadian Pacific (CP) upgraded to Buy from Hold at TD Securities. 4. Eni SpA (E) and Equinor (EQNR) were upgraded to Buy from Neutral at BofA/Merrill. 5. Fiesta Restaurant (FRGI) upgraded to Neutral from Underweight at Piper Jaffray with analyst Nicole Miller Regan saying the company has recently reported better than expected results and sustained a return to positive same-store sales trends. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Scotiabank lowered the firm's price target on Canadian Pacific Kansas City to C$124 from C$126 and keeps a Sector Perform rating on the shares.

Susquehanna analyst Bascome Majors lowered the firm's price target on Canadian Pacific Kansas City to $80 from $84 and keeps a Neutral rating on the shares. The firm views the company's nearer-term conservatism as prudent given the historic unpredictability of Canadian Teamsters labor negotiations, and remain on the sidleines primarily because of valuation.